Remsima®

Biosimilar medicine authorized by the European Commission

Remsima®

ACTIVE PRINCIPLE:
Infliximab

INDICATION:
Rheumatoid Arthritis
Crohn's disease
Ulcerative colitis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis

DATE:
10/09/2013

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE